A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung CancerShun Lu, Chengping Hu, Li Lü et al.|Journal of Thoracic Oncology|2015Cited by 44
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Li Zhang, Jun Zhao et al.|Journal of Thoracic Oncology|2021Cited by 44
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Huaize Geng, Jian Fang et al.|Signal Transduction and Targeted Therapy|2022Cited by 35
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].Yan Huang, Li Zhang, Yunpeng Liu et al.|PubMed|2012Cited by 5